AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.4 USD | -14.29% |
|
-39.48% | -67.39% |
| Apr. 12 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Apr. 12 | Sector Update: Health Care | MT |
Presentation Operator MessageOperator (Operator)Thank you for holding and welcome, everyone, t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.4
USD
Average target price
106.7
USD
Spread / Average Target
+1,875.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -67.39% | 132M | |
| -1.78% | 41.71B | |
| +47.70% | 41.56B | |
| +4.01% | 39.74B | |
| -15.14% | 25.61B | |
| +3.16% | 24.26B | |
| -24.08% | 18.55B | |
| -2.67% | 11.93B | |
| +24.76% | 11.93B | |
| +7.01% | 10.91B |
- Stock Market
- Equities
- AGEN Stock
- News Agenus Inc.
- Transcript : Agenus Inc., Q4 2022 Earnings Call, Mar 14, 2023
